Burnaby, BC Biotechnology and Pharmaceutical Companies directory and business contacts list
The following Burnaby, BC, Canada Biotechnology and Pharmaceutical Companies are among the many key British Columbia organizations listed in the BC Contacts Directory.Try BC Contacts today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.
Eros Roncaia, President
Sorin Group Canada Inc. - Mitroflow Division
5005 North Fraser Way
Burnaby, BC V5J 5M1
Tel. 604 412-5650
Fax. 604 412-5690
infofm9@mitroflow.com
www.sorin-hv.com
Geoff Davis, Ph.D., Chief Scientific Officer
Amgen British Columbia Inc.
7990 Enterprise Street
Burnaby, BC V5A 1V7
Tel. 604 676-8300
Fax. 604 676-8349
www.abgenix.com
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageCathy Shevchuk, Operations Manager
Silliker Canada Co. / Silliker JR Laboratories ULC
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
cshevchukb582@silliker.com
http://canada.silliker.com
www.silliker.com
Tom Redelmeier, President and Chief Executive Officer
Northern Lipids Inc.
8855 Northbrook Court
Burnaby, BC V5J 5J1
Tel. 604 222-2548
Fax. 604 222-2563
info5mwg5@northernlipids.com
www.northernlipids.com
Ernest McEachern, PhD, Co-Founder and Chief Executive Officer
Alectos Therapeutics Inc.
8999 Nelson Way
Burnaby BC V5A 4B5
Tel. 604 628-7129
Fax.
info6ak8tn@alectos.com
www.alectos.com
Dr. McEachern received his PhD from the University of British Columbia in synthetic organic chemistry and subsequently carried out post-doctoral studies at Stanford University. Dr. McEachern has eleven years of experience in the pharmaceutical industry.
He served in various capacities at AnorMed including leading a team in the hit-to-lead optimization and preclinical development of chemokine receptor antagonists as HIV entry inhibitors. Ultimately, these efforts culminated in Phase II clinical evaluation of a lead candidate.
Dr. McEachern was closely involved in developing the intellectual property strategy at AnorMed for the HIV entry inhibitor program. He is a co-founder, President, and Chief Executive Officer of Alectos Therapeutics. Dr. McEachern has also served as a member of the board of directors since founding of the company. Dr. McEachern is co-author on 44 publications and patents.
Cathy Cardinall, Quality Assurance and Safety Manager
Silliker Canada Co. / Silliker JR Laboratories ULC
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
ccardinallp0mkbq0pg@silliker.com
http://canada.silliker.com
www.silliker.com
Tammy Mullarky, Vice President, Strategic Planning and Business Development
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
infory7@inexpharm.com
www.tekmirapharm.com
September 29, 2008 - Tammy Mullarky has joined Tekmira effective immediately and will have responsibility for strategic planning and business development including securing additional licensing and collaborative research and development agreements for Tekmira's technology.
Ms. Mullarky joined Tekmira from Targeted Growth, Inc. where as Senior Vice President she was responsible for business functions including business development, intellectual property and finance. Prior to Targeted Growth, Ms. Mullarky was a senior executive at Epigenomics, AG where she completed a $100 million diagnostics partnership.
Ms. Mullarky also has experience as a venture capital partner and was a founder and senior executive at AnorMed Inc. Before AnorMed, she was a member of the corporate mergers and acquisitions team for F. Hoffmann- La Roche. Ms. Mullarky has a M.A. in Science Management from the Massachusetts Institute of Technology and a B.A. in Chemistry from Whitman College.
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageDr. John Webster, President, Chief Executive Officer and Founder
Welichem Biotech Inc.
316 - 4475 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 432-1703
Fax. 604 432-1704
jwebster7csmy0h@welichem.com
info7csmy0h@welichem.com
www.welichem.com
Brent Hale, Director, Human Resources
Maxxam Analytics International Corporation
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 639-8420 - direct
Tel. 604 734-7276
Fax. 604 731-2386
Brent.Halem70v3ae@maxxam.ca
infom70v3ae@maxxam.ca
http://maxxam.ca
January 30, 2007 - CANTEST Ltd. is pleased to announce the addition of Brent Hale as Director, Human Resources at CANTEST.
In addition to his in-depth knowledge of employment and labour law matters, Mr. Hale has experience in all areas of HR including compensation, recruitment, communications, organizational and leadership development and change management.
Jimmy Chang, Division Vice President
Silliker Canada Co. / Silliker JR Laboratories ULC
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
jchangn9b@silliker.com
http://canada.silliker.com
www.silliker.com
Vijay Sondhi, Chief Financial Officer & Chief Operating Officer
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
vsondhifgw@xenon-pharma.com
infofgw@xenon-pharma.com
www.xenon-pharma.com
Vijay Sondhi, Chief Financial Officer & Chief Operating Officer, joined Xenon in December 2004. Before joining Xenon, Mr. Sondhi spent 16 years in the high technology sector in Europe and the United States.
He held CFO and co-CEO positions with IXOS Software AG (subsequently acquired by Open Text Corporation) where he led the company's successful IPO on the NASDAQ and Frankfurt stock exchanges.
He was also CFO of Fidelio Software GmbH where he assisted in the sale of the company to MICROS Systems, Inc. Immediately prior to joining Xenon, Mr. Sondhi was Managing Director at Allianz Venture Partners, a EURO 300 million venture capital fund based in Munich.
He also served as a Venture Partner at Warburg Pincus in Europe. In addition, he has held several positions with Booz-Allen & Hamilton & SAP AG. Mr. Sondhi received an MBA from Columbia University, New York and a B.Sc. in Computer Science from the University of British Columbia, Vancouver.
Humphrey Tebit, Biopharmaceutics
Maxxam Analytics International Corporation
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 734-7276
Fax. 604 731-2386
Humphrey.Tebitl6bi@maxxam.ca
infol6bi@maxxam.ca
http://maxxam.ca
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageDr. Simon Pimstone, MD, PhD, FRCPC, President, Chief Executive Officer and Co-Founder
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
SPimstonef@xenon-pharma.com
infof@xenon-pharma.com
www.xenon-pharma.com
Xenon was launched in 1998 by Dr. Pimstone, a South African-born internal medicine specialist who trained with the department of medical genetics at the University of B.C, and chief scientific officer Michael Hayden, a professor of genetics at UBC. They describe Xenon as a clinical genetics-based drug discovery company.
"We believe Xenon has identified more disease-relevant genes, 17 to date, than any other company in the world, and we have advanced a number of those discoveries into drug programs," Pimstone said.
Simon Pimstone is a founder, Director, and President & Chief Executive Officer at Xenon Pharmaceuticals Inc. Dr. Pimstone received his MD from the University of Cape Town.
He is an internal medicine specialist (FRCPC) with an interest in cardiovascular disease. Prior to his specialization, he trained as a clinical research fellow with the Department of Medical Genetics at the University of British Columbia and obtained his PhD through the University of Amsterdam in cardiovascular genetics.
Dr. Pimstone has served as a consultant physician at the St. Paul's Hospital Lipid Clinic in Vancouver, as a Director of the Providence Healthcare Research Trust, a Director of the AllerGEN National Centre of Excellence, an Advisory Member of the SFU Biotech MBA program, and he is a Director of BIOTECanada. Dr. Pimstone is a member of the Young Presidents' Organization.
In 2005, he received the Business in Vancouver Top 40 under 40 Award and the Globe & Mail's Canadian Top 40 Under 40 Award in 2004. Dr. Pimstone is the author of numerous peer-reviewed publications and is also a regular guest speaker at international scientific meetings and healthcare conferences.
Owen Granger, Chief Financial Officer and Director
Lifebank Cryogenics Corporation
200 - 4475 Wayburne Drive
Burnaby, BC V5G 4X4
Tel. 604 738-2722
Fax. 604 738-2726
lifez43xk@lifebank.com
www.lifebank.com
Mr. Granger received a B.A. (honors) from the faculty of Business Administration, Simon Fraser University, in 1981 and has been a Certified Management Accountant since 1986. From 1983 to date he has been employed in a variety of senior accounting and financial management positions for public enterprises. He has been a director and senior financial officer of companies listed on the TSE, TSX, NASDAQ and over-the-counter markets.
In addition, since 1989, he has been a director and the part-time secretary treasurer of WestBond Enterprises Corporation, a public company engaged in the manufacture of disposable paper and polyethylene products for the medical, airline and industrial markets.
David Vocadlo, Ph.D., CSO, Co-founder
Alectos Therapeutics Inc.
8999 Nelson Way
Burnaby BC V5A 4B5
Tel. 604 628-7129
Fax.
infot7@alectos.com
www.alectos.com
Dr. David Vocadlo completed his PhD at the University of British Columbia in enzymology and carbohydrate synthesis. Following postdoctoral studies in chemical biology at the University of California at Berkeley, Dr. Vocadlo joined the Department of Chemistry at Simon Fraser University (SFU).
Dr. Vocadlo is the Canada Research Chair in Chemical Biology and a Scholar of the Michael Smith Foundation for Health Research. He is an associate professor in the Department of Chemistry and an associate member of the Department of Molecular Biology and Biochemistry at Simon Fraser University.
Dr. Vocadlo is a leader in understanding the mechanism of action of carbohydrate processing enzymes and using this information to interrogate these enzymes in biological systems. His research has focused on using a combination of chemical and biological approaches to study carbohydrate structures and to decode their roles in health and disease.
Dr. Vocadlo is a co-founder of Alectos and is the Chief Scientific Officer and Chair of the Scientific Advisory Board. He has served on the board of directors since founding of the company. Dr. Vocadlo has received several awards and is an author of over 60 scientific articles and patents.
August 11, 2010 - SFU Chemistry professor David Vocadlo announced a partnership between his drug discovery company Alectos Therapeutics and the pharmaceutical giant Merck to develop small molecule drug candidates that may be effective in the treatment of Alzheimer's disease.
Dr. Alex Berlin, Vice President of Research
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
ABerlins3mklr4n7@lignol.ca
infos3mklr4n7@lignol.ca
www.lignol.ca
Dr. Berlin developed postdoctoral R&D work in biorefinery of lignocellulosics at the Forest Products Biotechnology Group, Faculty of Forestry, University of British Columbia (Vancouver, BC, Canada). He has more than 15 years of R&D experience in this area including expertise in substrate pretreatment technologies, enzymatic hydrolysis of lignocellulosics, carbohydrate fermentation into cellulosic ethanol and other products, and development of lignin-based high-added value co-products.
He has authored or co-authored more than 50 scientific publications and invention patents. Dr. Berlin has extensive international industrial experience in business development for the Eastern European, South and North American biotech markets (bio-ethanol, food, and enzyme technologies).
Michael Rushton, P.Eng., Chief Operating Officer
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
MRushtoncyw5pf1@lignol.ca
infocyw5pf1@lignol.ca
www.lignol.ca
Rushton is a chemical engineer and business executive with more than 25 years of experience in the development and commercialization of technology. Mr. Rushton started his career in the oil industry and has subsequently been involved in the supply of technology to the pulp and paper, metal smelting and chemical process industries.
Most recently, Mr. Rushton has been involved with emerging technology in the alternative energy sector where he was President and CEO of Membrane Reactor Technologies Ltd.
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageJaime Williams, Managing Director
SISU Enterprises Co. Inc.
102 - 7635 North Fraser Way
Burnaby BC V5J 0B8
Tel. 604 420-6610
Fax. 604 420-4892
www.sisu.com/sisu/
Jaime Williams has also received a promotion, moving from SISU's Director of Marketing to fill the Managing Director role; Keith Didion's former position. Since joining SISU almost five years ago, Jaime has concentrated her efforts on launching research-driven, unique product formulations, and creating a consistent brand image that is supported with retail education initiatives.
The next phase of her career will focus on expanding SISU within Canada, while maintaining its brand strength, premium standard, and commitment to retailers; to ensure SISU is at the forefront for the Canadian consumer.
John R. North, Ph.D., Chief Operating Officer
Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby BC V5A 4T8
Tel. 604 225-2251
Fax. 604 225-2257
jnorthi5s7@inimexpharmaceuticals.com
infoi5s7@inimexpharma.com
www.inimexpharma.com
Dr. North led the early development of Inimex' IDR technology, serving as EVP of R&D in 2004 and then President and Chief Executive Officer 2005 to 2009. Prior to joining Inimex, he served as Sr. Vice President, Scientific Affairs and Chief Scientific Officer of QLT Inc.
Earlier in his career, Dr. North was Managing Director of Monotech Laboratories Ltd., Biotechnology Consultant at PA Technology Ltd. and spent 12 years with various U.K. and U.S.-based subsidiaries within the Beaufour Ipsen Group, most recently as Head of Exploratory Development at Ipsen International in the U.K. Dr. North received a Ph.D. in Immunology and an M.A. in Natural Sciences from the University of Cambridge, England.
Dr. Peter Lutwyche, Vice President, Pharmaceutical Development
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
info40@inexpharm.com
www.tekmirapharm.com
Dr. Lutwyche joined Tekmira's subsidiary company, Protiva Biotherapeutics Inc., in February 2008, and has responsibility for manufacturing, process development and quality control for all Tekmira product candidates as well as supporting Tekmira's collaborative partners as they advance products based on Tekmira's technology.
Tekmira expects three siRNA product candidates using the company's SNALP delivery technology will be in clinical development in 2009.
Dr. Lutwyche joined Tekmira from QLT Inc., where he was employed for ten years, most recently as Director, Pharmaceutical Development. During his tenure at QLT, Dr. Lutwyche contributed to the development and commercialization of Visudyne as well as leading manufacturing and chemistry efforts for numerous preclinical and clinical stage products.
Prior to QLT, he was a research scientist at Inex Pharmaceuticals Corporation working with lipid-based formulations of nucleic acids and antibiotics. Dr. Lutwyche holds a Ph.D. in Chemistry from the University of British Columbia.
Gwen Epstein, Lab Manager
Lifebank Cryogenics Corporation
200 - 4475 Wayburne Drive
Burnaby, BC V5G 4X4
Tel. 604 738-2722
Fax. 604 738-2726
life8pgc1ue@lifebank.com
www.lifebank.com
As the Laboratory Manager of Lifebank; Gwen Epstein is responsible for supervising the laboratory operations of the cord blood bank, providing expertise in the development of laboratory procedures, training and ensuring compliance with the regulatory requirements of a cellular therapy laboratory.
Gwen graduated from the University of BC with a BSc, major in Microbiology and completed certification as a registered medical technologist with the CSMLS. Prior to the position at Lifebank; Gwen was the Coordinator of the Nucleic Acid Testing Lab and the HLA lab at the Canadian Blood Services. The experience in HLA typing was obtained through experience working in the Immunology Lab at VGH. Gwen just completed training as an assessor for the AABB.
Charles J. Cohen, Vice President, Discovery Research
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
CCoheny2k6ib2k@xenon-pharma.com
infoy2k6ib2k@xenon-pharma.com
www.xenon-pharma.com
February 6, 2008 - Xenon Pharmaceuticals, a drug discovery and development company, announced it has appointed Charles J. Cohen as Vice President, Discovery Research.
"We are delighted to welcome Charlie to the Xenon team" commented Simon Pimstone, Xenon's President and CEO. "Charlie brings a unique combination of drug discovery experience and leadership including in areas that are highly relevant to Xenon such as pain.
With a drug candidate for pain currently in clinical trials, and a backup compound expected to follow, we are certain that Charlie's background will be of great benefit to Xenon. In addition to his experience in the pain area, Charlie brings broad and diverse expertise which will be applicable to our multiple discovery and pre-clinical programs."
Dr. Cohen has spent the past approximately 25 years in the pharmaceutical/biotechnology industry with positions at Bayer Pharmaceuticals, Merck & Co and Vertex Pharmaceuticals. He held senior scientific positions and has published widely in the area of pain and more broadly in cellular neuroscience and neurology. Dr. Cohen received his PhD in Biophysics and Theoretical Biology from the University of Chicago.
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageDon Enns, President, Chief Executive Officer and Board Member
Maxxam Analytics International Corporation
4606 Canada Way - Burnaby Life Sciences Centre
Burnaby, BC V5G 1K5
Tel. 604 639-2609 - direct
Tel. 604 734-7276
Fax: 604 731-2386
Don.Ennsxn51d39@maxxam.ca
infoxn51d39@maxxam.ca
http://maxxam.ca
Don has well over 20 years of laboratory management experience. He obtained his BSc from Trinity Western University and an MBA designation from the University of British Columbia.
He currently sits on the Boards of several local companies in the Life Sciences field and has been President of organizations including the Canadian Association for Environmental Analytical Laboratories (CAEAL) and the BC Water & Waste Association (BCWWA.)
Don has been instrumental in CANTEST's expansion into the European and Southeast Asian markets. His experience overseas includes laboratory consulting such as on new laboratory construction, business development and mergers & acquisitions.
Raymond Ma, Vice President of Process Development
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
RMaeuc0hp@lignol.ca
infoeuc0hp@lignol.ca
www.lignol.ca
Raymond Ma is a well rounded executive with extensive experience in operation, process design, project execution and technology management. He has successfully managed a variety of technology development projects throughout his professional career.
Heather Harris-Harper, Director, Clinical Operations, Clinical Research
Maxxam Analytics International Corporation
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 734-7276
Fax. 604 731-2386
infoo1oyjtw@maxxam.ca
http://maxxam.ca
January 30, 2007 - As Director, Clinical Operations, Ms. Harris-Harper's responsibilities include the direction, planning and execution of clinical trials, ensuring operational excellence for CANTEST Clinical Research's international corporate clientele.
Ms. Harris-Harper brings to CANTEST 20 years of experience in the conduct of pharmaceutical industry sponsored clinical trials and has held progressive positions in clinical trial monitoring, management and operational supervision at several leading multinational biotechnology and pharmaceutical companies.
Rajender Kamboj, Ph.D., Executive Vice President, Drug Discovery
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
RKamboj5mwg@xenon-pharma.com
info5mwg@xenon-pharma.com
www.xenon-pharma.com
Rajender Kamboj, Executive Vice President, Drug Discovery joined Xenon in April 2002. Dr. Kamboj was previously the Vice President and Chief Scientific Officer of Allelix Biopharmaceuticals Inc. (part of NPS Pharmaceuticals, Inc) where he had primary responsibility for managing their drug discovery programs.
In his 12 years with Allelix/NPS, Dr. Kamboj managed research teams covering all aspects of drug discovery and development, from initial research to clinical trials.
Under his leadership at Allelix/NPS, Dr. Kamboj also established, implemented and managed significant corporate partnerships with Eli Lilly, Hoechst Marion Roussel (now Aventis) and Janssen Pharmaceutica (part of Johnson & Johnson).
He led the development of nine drug discovery programs in neurological, metabolic and other therapeutic areas. During his tenure, four drug development programs were independently advanced into clinical studies by Allelix/NPS and three programs partnered with Eli Lilly, Aventis and Johnson & Johnson were advanced into late-stage pre-clinical development. Dr. Kamboj received his PhD from the University of Adelaide in Australia.
Kent Toy, Director of Finance
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
KToyh37mxcyi@lignol.ca
infoh37mxcyi@lignol.ca
www.lignol.ca
Kent Toy has extensive finance and administration experience with a range of private and public technology companies, providing full financial reporting and project accounting management.
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pagePaul Hughes, Vice President, Corporate Development and Communications
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800 X 110 - direct
Tel. 604 222-9800
Fax. 604 222-9801
phughes7i8m4@lignol.ca
info7i8m4@lignol.ca
www.lignol.ca
Paul Hughes has extensive international experience and expertise within the alternative/renewable energy sector gained within North America, Europe and Asia.
Mr. Hughes has co-founded energy companies in Europe and North America, has led an energy company from start-up through to IPO and has successfully raised private equity within multiple energy technology companies.
Mr. Hughes has also held senior business development and corporate finance roles in the UK and US utilities. Mr. Hughes holds a BSc (Hons) in Business from Aston University, UK, an Executive MBA from Ashridge, UK and is a Chartered Accountant.
Marcus Maguire, B.Sc. Honors, Senior Vice President, Western Canada Operations
AGAT Laboratories - British Columbia Region Main Office
3104 Beta Avenue
Burnaby BC V5G 4K4
Tel. 778 328-8787
Fax. 778 328-8795
infovdbbd@agatlabs.com
www.agatlabs.com
March, 2010 - We are pleased to announce the appointment of Marcus Maguire to the position of Senior Vice President of Western Canada operations. A native Calgarian, Marcus will oversee AGAT's Energy, Environmental and Mining Geochemistry divisions throughout Western Canada.
The consolidation of these divisions under Maguire, and their further expansions will provide a unique opportunity to establish an enhanced business relationship with our many clients; providing multi-divisional analytical service requirements with one laboratory vendor. Marcus graduated from St. Francis Xavier University, with an Honours degree in Chemistry and joined AGAT Laboratories in 1996 as an Inorganic Analyst in the Oil and Gas division specializing in metals analysis.
Shortly thereafter, Marcus transferred to the newly formed Environmental division. After improving several metals analysis methods, Marcus was promoted to the position of Quality Assurance Officer for Alberta where he directed significant improvements in AGAT Laboratories' Quality Assurance, Quality Control systems and under his direction, in 1997 the ISO 9000 registration was achieved.
This registration was the first step in paving the way for AGAT Laboratories' present day Quality Assurance Quality Control systems and extensive network of accreditations achieved at our Canadian laboratories. In 1998, after serving as the Manager of the Calgary Environmental Project Management team, Marcus was promoted to General Manager of AGAT Laboratories' Environmental division.
In 1999, Marcus transferred to Ontario to directly oversee the Eastern Canadian expansion of AGAT's new Environmental division. Under his leadership and vision, new laboratories and operations were established in Mississauga, London, Hamilton, Kitchener, Montreal, Quebec City and Halifax.
In 2005, as the Senior Vice President of Environmental Operations, Marcus oversaw AGAT's Western Canadian Environmental service expansions resulting in the creation of new Environmental laboratories in Calgary, Grande Prairie and the currently ongoing expansions in Edmonton and Vancouver.
In 2009, Marcus directed the expansion of services into the precious metals mining industry with the creation of new laboratories to supplement the existing Calgary Rock Properties laboratory which services the Energy and Mining industries. Under Maguire's leadership, AGAT established a new mining laboratory in Mississauga, Ontario and opened sample preparation facilities in Vancouver, Kelowna, Sudbury and Whitehorse.
Martin (Marty) McConnell, C.A., Chief Financial Officer
Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby BC V5A 4T8
Tel. 604 225-2251
Fax. 604 225-2257
inforrb5onsi@inimexpharma.com
www.inimexpharma.com
For the past five years Marty has worked with emerging high tech and Biotech companies as part-time CFO focused on strategic financial issues. For the prior 18 years he was CFO for two midsize public (TSX, Nasdaq) Canadian high tech companies, from 1993 to 2002 with Spectrum Signal Processing Inc. and from 1985 to 1993 at Epic Data International Inc. Mr. McConnell holds a B. Comm. from the University of British Columbia and is a Chartered Accountant.
Ray Cheung, Division President
Silliker Canada Co. / Silliker JR Laboratories ULC
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
rcheungm70v3ae@silliker.com
http://canada.silliker.com
www.silliker.com
Ray graduated from UBC with a BSc (Food Science) in 1975. He has worked as a microbiology lab technician at Provincial Health Laboratory before joining BC Provincial Dairy and Food Laboratory, where he supervised staff testing raw and finished dairy products.
In 1988, the provincial government privatized the Dairy Testing Laboratory. Ray and associates purchased the laboratory and in 1989, JR Laboratories Inc. was formed. Ray is a major shareholder and Laboratory Director, while his partner, Jimmy Chang, is the President. JR Laboratories Inc. continues to be the only BC government designated and certified lab for dairy and food analysis.
Ian Mortimer, Senior Vice President, Finance and Chief Financial Officer
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
infon9b@inexpharm.com
www.tekmirapharm.com
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageDr. Humbert DelliColli, Director of Lignin Development
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
HDelliCollifgw@lignol.ca
infofgw@lignol.ca
www.lignol.ca
Dr. DelliColli has more than 30 years of experience in the development and production of lignin and other specialty chemicals. Prior to joining Lignol, Dr. DelliColli held a series of progressively senior positions with MeadWestvaco Corporation, the world's leading commercial-scale producer of Kraft lignin derivatives.
Oreola Donini, Ph.D., Senior Director, Preclinical R&D
Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby BC V5A 4T8
Tel. 604 225-2251
Fax. 604 225-2257
infol6bi@inimexpharma.com
www.inimexpharma.com
Dr. Donini has 10 years experience in drug discovery, optimization and development and has lead the discovery, selection and advancement of Inimex' lead drug candidate, IMX942.
Prior to joining Inimex, Dr. Donini was involved in drug discovery and development at Kinetek Pharmaceuticals, managing a key program with an external partner, as well as initiating and managing a team providing informatics analysis and support to the company at large. Dr. Donini received her PhD in Chemistry from Queen's University in Kingston, Ontario and completed post-doctoral studies at the University of California, San Francisco.
Dr. William Armiger, Vice President, Lignin Application Development
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
WArmigerf@lignol.ca
infof@lignol.ca
www.lignol.ca
Dr. Armiger has more than 25 years of experience in the specialty-chemicals, pharmaceutical, biotechnology and environmental-technology industries and is the former CEO and cofounder of BioChemInsights Inc.
He also has extensive experience developing, licensing and commercializing products and process technology for use in industrial biofuels and wastewater treatment. Prior to joining Lignol, Dr. Armiger was engaged as Vice President of Venture Catalysts and also previously held senior consulting positions with The Catalyst Group and Arthur D. Little (“ADL").
Rob MacArthur, Communications
Maxxam Analytics International Corporation
4606 Canada Way
Burnaby BC V5G 1K5
Tel. 604 639-8431 - direct
Tel. 604 734-7276
Fax. 604 731-2386
rob.macarthurz43xk@maxxamanalytics.com
infoz43xk@maxxamanalytics.com
http://maxxam.ca
Vinay Chhatre, Manager Sales & Business Development
Northern Lipids Inc.
8855 Northbrook Court
Burnaby, BC V5J 5J1
Tel. 604 638-5631 - direct
Tel. 604 222-2548
Fax. 604 222-2563
infot7@northernlipids.com
www.northernlipids.com
Save time and money building your business with BC Contacts, and get connected to industries, companies and the people running them of greatest value to you. Try BC Contacts today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageRoss MacLachlan, President, Director and Chief Executive Officer
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800 X 107 - direct
Tel. 604 222-9800
Fax. 604 222-9801
RMacLachlans3mklr4n7@lignol.ca
infos3mklr4n7@lignol.ca
www.lignol.ca
MacLachlan has extensive experience in project financing, including a former role in corporate finance at Haywood Securities Inc. Mr. MacLachlan also has a successful track record in technology development and marketing, having worked successfully with Xerox Canada and Systems Auditing, a company which he founded.
MacLachlan has worked with companies in both the conventional and alternative energy sectors. He has been actively involved in raising capital for emerging technology companies and has acted as consultant or director for many of them.
Gurminder Minhas, Director, Technology Deployment
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800 X 115 - direct
Tel. 604 222-9800
Fax. 604 222-9801
GMinhascyw5pf1@lignol.ca
infocyw5pf1@lignol.ca
www.lignol.ca
Gurminder Minhas is the former Head of Research for the Pulp and Paper Division of Canfor Corp. and has extensive experience in process implementation for new technologies, as well as plant performance and optimization.
Mark Murray, Ph.D., President & Chief Executive Officer
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
info16rz8@inexpharm.com
www.tekmirapharm.com
See also
Mark Murray, Ph.D., President & Chief Executive Officer
Protiva Biotherapeutics Inc.
100 - 3480 Gilmore Way
Burnaby, BC V5G 4W7
Tel. 604 630-5063 - direct
Tel. 604 630-5061
Fax. 604 630-5103
information16rz8@protivabio.com
www.protivabio.com
Dr. Mark Murray has led Protiva since its inception in the summer of 2000. Dr. Murray has over 25 years of experience in both the R&D and business development facets of the biotechnology industry.
He has held senior management positions at ZymoGenetics and Xcyte Therapies prior to joining Protiva. Since entering the biotechnology industry he has successfully completed numerous and varied partnering deals, directed successful product development programs, been responsible for strategic planning programs, raised financing and executed extensive business development initiatives.
During his R&D career, Dr. Murray worked extensively on three programs that resulted in FDA approved drugs, including the first growth factor protein approved for human use, a program he led for several years.
Dr. Murray obtained his Ph.D. from the University of Oregon Health Sciences University and was a Damon Runyon-Walter Winchell post-doctoral research fellow for three years at the Massachusetts Institute of Technology.
